파마메디잡 :: 기업정보 상세보기

퀴아젠코리아 유한회사

www.qiagen.com

	대표자명		베른트우더

	주요사업내용		과학기자재 및 시약 도매/서비스

	업종		생명공학/시약

	기업형태		외국계기업

	상장여부		나스닥

	설립연도		2006년

	회사주소		서울 금천구 가산동 우림라이온스밸리 C동 1012호

	이메일		hr-korea@qiagen.com

	전화번호		02-2626-5716

	팩스번호		02-2626-5717

회사소개

<P>QIAGEN is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA, and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules, such as the DNA of a specific virus, visible for subsequent analysis. </P>
<P>We have developed and market more than 500 sample and assay products as well as automated solutions for such consumables. The company provides these products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the <I>digene</I> HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. </P>
<P>As of December 31, 2011 QIAGEN employed nearly 3,900 people in over 35 locations worldwide.</P>

연혁 및 실적

<H1>Corporate History — Milestones and Highlights</H1>
<P>QIAGEN was founded 1984 as a spin-off at the University of Düsseldorf. Since then the company has continuously developed and turned into what is today the world's leading provider for innovative sample and assay technologies for research in molecular diagnostics, applied testing, pharma and academic research. </P>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>2012</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>QIAGEN adds several biomarkers associated with brain and lung cancers as well as other malignancies to its portfolio. 
<LI>QIAGEN and the Max Planck Institute join forces to develop a new test for assessment of active TB risk in patients with latent TB infection. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>2011</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>QIAGEN submits two KRAS assays for regulatory approval as companion diagnostics for colorectal cancer treatments in the US and enters further co-development agreements. 
<LI>Acquisition of QuantiFERON technology that allows for the detection of many diseases far earlier than other methods. 
<LI>QIAGEN acquires a majority stake in the French company Ipsogen and gains access to a leading portfolio of blood cancer tests. 
<LI>Further expansion in Asia with new subsidiaries in India and Taiwan. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>2010</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>QIAGEN acquires a new detection technology for Point of Need. The instruments are highly affordable, portable and generate results in 5 to 15 minutes. 
<LI>This technology plays a key role in a pilot project run by the UN Food and Agriculture Organization and the International Atomic Energy Agency to contain animal diseases in emerging countries. 
<LI>QIAGEN launches QIAsymphony RGQ, a highly flexible modular automation platform covering entire laboratory workflows. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>2009</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>QIAGEN enhances its portfolio with several PCR-based assay panels covering entire biological pathways and diseases, thereby strengthening its offering for pharmaceutical research. 
<LI>QIAGEN acquires DxS Ltd., giving the company a leadership position in personalized healthcare. 
<LI>QIAGEN’s technologies play a key role in the fight against the global Swine Flu pandemic. 
<LI>With the real-time PCR cycler Rotor-Gene Q and QIAgility for automated assay setup, QIAGEN enables the automation of complete laboratory workflows from sample to result. </LI></UL></TD>
<TR class=headerRow>
<TD>2008</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>Acquisition of Pyrosequencing, a detection technology that works on a single base-pair level and allows the identification of unknown DNA sequences or mutations. 
<LI>QIAsymphony SP launches as the first system in a series of modular instruments, designed to automate entire laboratory workflows. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>2007</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>QIAGEN merges with Digene Corp., creating the market and technology leader in molecular diagnostics. 
<LI>QIAGEN introduces QIAcube, a revolutionary platform which fully automates the processing of QIAGEN consumable products. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>2006</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>QIAGEN acquires an assay technology which allows for the testing of multiple pathogens in a single run (“multiplexing”). 
<LI>QIAGEN establishes its Asia regional headquarters in Shanghai. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>2005</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>QIAGEN acquires a leading position in molecular diagnostics by adding various sets of PCR-based molecular tests to its portfolio. 
<LI>Development of the <EM>artus</EM> influenza kit for the rapid detection of all known variants of the Avian Flu virus H5N1. 
<LI>QIAGEN receives world’s first governmental clearance for an Avian Flu assay (through its subsidiary PG Biotech in China). 
<LI>QIAGEN launches the first human whole genome siRNA set worldwide. SiRNAs are RNA molecules that can reduce or shut down activity of individual genes. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>2004</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>QIAGEN’s QIAamp becomes the world’s first standalone product for sample preparation to receive the CE mark. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>2002</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>Relocation of US headquarters from Valencia, CA, to Germantown, MD. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>2001</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>QIAGEN launches PAXgene, the first product that consolidates and integrates key steps of sample collection, stabilization and purification. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>1999</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>PreAnalytiX, a joint venture with Becton, Dickinson and Company, is established. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>1998</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>QIAGEN significantly expands its capabilities in automation. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>1997</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>Initial Public Offering is completed on Deutsche Boerse (Prime Standard), Frankfurt. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>1996</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>QIAGEN N.V. (Holding) established in Venlo, The Netherlands. 
<LI>Initial Public Offering is completed on NASDAQ, New York. 
<LI>QIAGEN introduces the BioRobot 9600, its first benchtop workstation, which automates purification technologies. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>1986</TD></TR>
<TR>
<TD vAlign=top>
<UL>
<LI>QIAGEN revolutionizes molecular biology by introducing the first “Plasmid-Kit.“ The discovery reduces the time needed for the preparation of plasmids, little ring-shaped DNA molecules of a bacteria’s cell, from 2-3 days to 2 hours. </LI></UL></TD></TR></TBODY></TABLE>
<TABLE class="standardTable pointerTable" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR class=headerRow>
<TD>1984</TD></TR>
<TR style="BACKGROUND-COLOR: #efefef">
<TD vAlign=top>
<UL>
<LI>QIAGEN is founded in Duesseldorf, Germany. </LI></UL></TD></TR></TBODY></TABLE>

퀴아젠코리아 생명과학 분야 영업사원 모집	대학(4년) 졸업 \| 3년↑ \| 서울 전지역, 대전 전지역 \| 채용시

퀴아젠코리아 Customer Care Representative	대학(2~3년) 졸업 \| 경력무관 \| 서울 전지역 \| 채용시